Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Anthony Meluch

Hematology & Oncology Nashville, TN Medical Doctor

NPI 1679521090 CMS profile 348737

2004 Hayes St Ste 350, Nashville, TN 37203

Open in the dashboard

General payments

$80,410

277 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Anthony Meluch of Nashville, TN is reported in the CMS Open Payments database as having received $80,410 across 277 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $50 2
2023 General $2,065 53
2022 General $9,372 23
2021 General $7,693 8
2020 General $3,455 26
2019 General $57,775 165

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Meluch
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Anthony Meluch were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Anthony Meluch Hematology & Oncology median Middle half National median
2019 $57,775 $529 $121–$2,516 $163
2020 $3,455 $339 $82–$2,213 $114
2021 $7,693 $263 $49–$1,965 $132
2022 $9,372 $416 $103–$2,395 $149
2023 $2,065 $542 $125–$2,646 $160
2024 $50 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Exelixis Inc. $73,195 72 payments
  2. Genzyme Corporation $2,113 9 payments
  3. Aveo Pharmaceuticals, Inc. $1,148 3 payments
  4. Merck Sharp & Dohme Corporation $469 19 payments
  5. AstraZeneca Pharmaceuticals LP $321 11 payments
  6. E.R. Squibb & Sons, L.L.C. $291 12 payments
  7. Novartis Pharmaceuticals Corporation $249 14 payments
  8. Janssen Biotech, Inc. $229 13 payments
  9. Amgen Inc. $223 11 payments
  10. Genentech USA, Inc. $200 7 payments
  11. Other $1,971 106 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $54,203 16 payments
  2. Travel and Lodging $12,345 25 payments
  3. Food and Beverage $6,308 231 payments
  4. Honoraria $4,620 1 payment
  5. Consulting Fee $2,910 2 payments
  6. Education $23 2 payments
Products named General payments · program years 2019–2024
  1. CABOMETYX Oncology $65,451 64 payments
  2. CABOMETYX Oncology $7,681 7 payments
  3. JEVTANA $2,028 5 payments
  4. FOTIVDA $1,148 3 payments
  5. KEYTRUDA $414 16 payments
  6. OPDIVO $240 9 payments
  7. XGEVA $165 7 payments
  8. IMBRUVICA $145 9 payments
  9. LIBTAYO $134 6 payments
  10. DARZALEX $119 8 payments
  11. Other $3,665 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

277 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record